Immune regulation of human herpesviruses and its implications for human transplantation

American Journal of Transplantation

Volumn 13, Issue SUPPL. 3, 2013, Pages 9-23

  Smith, C ^a   Khanna, Rajiv ^a  

^a Australian Centre for Vaccine Development   (Australia)

Author keywords

Antiviral immunity; Cell mediated immunity; Cellular immunity; Cellular immunology; Cytomegalovirus (CMV); Cytomegalovirus infection; Epstein Barr virus (EBV); Herpes simplex virus; Herpes zoster; HHV 6; HHV 8; Immunotherapy

Indexed keywords

ANIMAL; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 8; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; METABOLISM; METHODOLOGY; REVIEW; SIMPLEXVIRUS; TRANSPLANTATION;

ANIMALS; CYTOMEGALOVIRUS INFECTIONS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HERPESVIRUS 6, HUMAN; HERPESVIRUS 8, HUMAN; HUMANS; IMMUNE EVASION; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, INNATE; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; SIMPLEXVIRUS; TRANSPLANTATION;

MLCS; MLOWN;

EID: 84880143855     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12005     Document Type: Article

References (163)

1. Johnson DC, Hill AB. Herpesvirus evasion of the immune system. Curr Top Microbiol Immunol 1998; 232: 149-177.
2. VossenMT,Westerhout EM, Soderberg-Naucler C,Wiertz EJ. Viral immune evasion: A masterpiece of evolution. Immunogenetics 2002; 54: 527-542.
3. Burrows SR, Moss DJ, Khanna R. Understanding human T-cellmediated immunoregulation through herpesviruses. Immunol Cell Biol 2011; 89: 352-358.
4. Kutok JL,Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 2006; 1: 375-404.
5. Griffin BD, Verweij MC, Wiertz EJ. Herpesviruses and immunity: The art of evasion. Vet Microbiol 2010; 143: 89-100.
6. Cainelli F, Vento S. Infections and solid organ transplant rejection: A cause-and-effect relationship? Lancet Infect Dis 2002 ; 2: 539-549.
7. Paludan SR, Bowie AG, Horan KA, Fitzgerald KA. Recognition of herpesviruses by the innate immune system. Nat Rev Immunol 2011; 11: 143-154.
8. Orange JS, Biron CA. Characterization of early IL-12, IFNalphabeta, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection. J Immunol 1996; 156: 4746-4756.
9. Boehme KW, Guerrero M, Compton T. Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. J Immunol 2006; 177: 7094-7102.
10. Compton T, Kurt-Jones EA, Boehme KW, et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol 2003; 77: 4588-4596.
11. Iwakiri D, Zhou L, Samanta M, et al. Epstein-Barr virus (EBV)- encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med 2009; 206: 2091-2099.
12. Lund J, Sato A, Akira S,Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 2003; 198: 513-520.
13. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9: 503-510.
14. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002; 296: 1323-1326.
15. Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, Lopez- Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004; 104: 3664-3671.
16. Foley B, Cooley S, Verneris MR, et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012; 119: 2665-2674.
17. Lopez-Verges S, Milush JM, Schwartz BS, et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A 2011; 108: 14725-14732.
18. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature 2009; 457: 557-561.
19. Dechanet J, Merville P, Lim A, et al. Implication of gammadelta T cells in the human immune response to cytomegalovirus. J Clin Invest 1999; 103: 1437-1449.
20. Pitard V, Roumanes D, Lafarge X, et al. Long-term expansion of effector/memory Vdelta2-gammadelta T cells is a specific blood signature of CMV infection. Blood 2008; 112: 1317-1324.
21. Couzi L, Pitard V, Netzer S, et al. Common features of gammadelta T cells and CD8(+) alphabeta T cells responding to human cytomegalovirus infection in kidney transplant recipients. J Infect Dis 2009; 200: 1415-1424.
22. Vermijlen D, BrouwerM, Donner C, et al. Human cytomegalovirus elicits fetal gammadelta T cell responses in utero. J Exp Med 2010; 207: 807-821.
23. Khan N, Hislop A, Gudgeon N, et al. Herpesvirus-specific CD8 T cell immunity in old age: Cytomegalovirus impairs the response to a coresident EBV infection. J Immunol 2004; 173: 7481-7489.
24. Khan N, Shariff N, Cobbold M, et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002; 169: 1984-1992.
25. Karrer U, Sierro S,Wagner M, et al.Memory inflation: Continuous accumulation of antiviral CD8+T cells over time. J Immunol 2003; 170: 2022-2029.
26. Munks MW, Cho KS, Pinto AK, Sierro S, Klenerman P, Hill AB. Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection. J Immunol 2006; 177: 450-458.
27. Pourgheysari B, Khan N, Best D, Bruton R, Nayak L,Moss PA. The cytomegalovirus-specific CD4+ T-cell response expands with age and markedly alters the CD4+ T-cell repertoire. J Virol 2007; 81: 7759-7765.
28. Derhovanessian E, Maier AB, Hahnel K, et al. Infection with cytomegalovirus but not herpes simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans. J Gen Virol 2011; 92(Pt 12): 2746-2756.
29. Seckert CK, Schader SI, Ebert S, et al. Antigen-presenting cells of haematopoietic origin prime cytomegalovirus-specific CD8 Tcells but are not sufficient for driving memory inflation during viral latency. J Gen Virol 2011; 92(Pt 9): 1994-2005.
30. Torti N, Walton SM, Brocker T, Rulicke T, Oxenius A. Non- Hematopoietic Cells in Lymph Nodes Drive Memory CD8 T Cell Inflation during Murine Cytomegalovirus Infection. PLoS Pathog 2011; 7: e1002313.
31. Soderberg-Naucler C, Streblow DN, Fish KN, Allan-Yorke J, Smith PP, Nelson JA. Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent. J Virol 2001; 75: 7543-7554.
32. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997; 91: 119-126.
33. Appay V, Dunbar PR, CallanM, et al. Memory CD8+T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002; 8: 379-385.
34. van Leeuwen EM, de Bree GJ, Remmerswaal EB, et al. IL-7 receptor alpha chain expression distinguishes functional subsets of virus-specific human CD8+ T cells. Blood 2005; 106: 2091-2208.
35. Kern F, Khatamzas E, Surel I, et al. Distribution of human CMVspecific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoforms. Eur J Immunol 1999; 29: 2908-2915.
36. Wang EC, Moss PA, Frodsham P, Lehner PJ, Bell JI, Borysiewicz LK. CD8highCD57 +T lymphocytes in normal, healthy individuals are oligoclonal and respond to human cytomegalovirus. J Immunol 1995; 155: 5046-5056.
37. Wang EC, Taylor-Wiedeman J, Perera P, Fisher J, Borysiewicz LK. Subsets of CD8+, CD57+ cells in normal, healthy individuals: Correlations with human cytomegalovirus (HCMV) carrier status, phenotypic and functional analyses. Clin Exp Immunol 1993; 94: 297-305.
38. van Leeuwen EM, Gamadia LE, Baars PA, Remmerswaal EB, ten Berge IJ, van Lier RA. Proliferation requirements of cytomegalovirus-specific, effector-type human CD8+ T cells. J Immunol 2002; 169: 5838-5843.
39. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIVspecific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350-354.
40. Duraiswamy J, Ibegbu CC, Masopust D, et al. Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. J Immunol 2011; 186: 4200-4212.
41. Crough T, Beagley L, Smith C, Jones L, Walker DG, Khanna R. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol Cell Biol 2012; 90: 872-880.
42. Lachmann R, Bajwa M, Vita S, et al. Polyfunctional T cells accumulate in large human cytomegalovirus-specific T cell responses. J Virol 2012; 86: 1001-1009.
43. Casazza JP, Betts MR, Price DA, et al. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med 2006; 203: 2865-2877.
44. Harari A, Enders FB, Cellerai C, Bart PA, Pantaleo G. Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure. J Virol 2009; 83: 2862-2871.
45. Chattopadhyay PK, Betts MR, Price DA, et al. The cytolytic enzymes granyzme A, granzyme B, and perforin: Expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukoc Biol 2009; 85: 88-97.
46. Remmerswaal EB, Havenith SH, Idu MM, et al. Human virusspecific effector-type T cells accumulate in blood but not in lymph nodes. Blood 2012; 119: 1702-1712.
47. Kern F, Surel IP, Faulhaber N, et al. Target structures of the CD8(+)-T-cell response to human cytomegalovirus: The 72- kilodalton major immediate-early protein revisited. J Virol 1999; 73: 8179-8184.
48. Wills MR, Carmichael AJ,Mynard K, et al. The human cytotoxic Tlymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996; 70: 7569-7579.
49. Khan N, Cobbold M, Keenan R, Moss PA. Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. J Infect Dis 2002; 185: 1025-1034.
50. Elkington R, Walker S, Crough T, et al. Ex vivo profiling of CD8+- T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003; 77: 5226-5240.
51. Tey SK, Goodrum F, Khanna R. CD8+ T-cell recognition of human cytomegalovirus latency-associated determinant pUL138. J Gen Virol 2010; 91(Pt 8): 2040-2048.
52. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate thememory compartments of exposed subjects. J ExpMed 2005; 202: 673-685.
53. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: Lessons from Epstein-Barr virus. Annu Rev Immunol 2007; 25: 587-617.
54. Dupre L, Andolfi G, Tangye SG, et al. SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells. Blood 2005; 105: 4383-4389.
55. Hislop AD, Palendira U, Leese AM, et al. Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood 2010; 116: 3249-3257.
56. Palendira U, Low C, Chan A, et al. Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP. PLoS Biol 2011; 9: e1001187.
57. Hislop AD, Gudgeon NH, Callan MF, et al. EBV-specific CD8+ T cell memory: Relationships between epitope specificity, cell phenotype, and immediate effector function. J Immunol 2001; 167: 2019-2029.
58. Kieff E. Epstein-Barr virus: New insights. Journal of Infectious Diseases. 1995; 171: 1323-1324.
59. Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu RevMicrobiol 2000; 54: 19-48.
60. Smith C, Beagley L, Khanna R. Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+T cells correlates with increased resistance to galectin-1-mediated suppression. J Virol 2009; 83: 6192-6198.
61. Smith C, Wakisaka N, Crough T, et al. Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBVencoded oncogene LMP-1 through self-aggregation. Blood 2009; 113: 6148-6152.
62. Tellam J, Connolly G, Green KJ, et al. Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J Exp Med 2004; 17: 1421-1431.
63. Tellam J, Fogg MH, RistM, et al. Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes. J Exp Med 2007; 204: 525-532.
64. Khanna R, Sherritt M, Burrows SR. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: Potential use of gp350/gp85 CTL epitopes for vaccine design. J Immunol 1999; 162: 3063-3069.
65. Lepone L, Rappocciolo G, Knowlton E, et al. Monofunctional and polyfunctional CD8+ T cell responses to human herpesvirus 8 lytic and latency proteins. Clin Vaccine Immunol 2010; 17: 1507-1516.
66. Guihot A, Oksenhendler E, Galicier L, et al. Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8-specific CD8+ T cells. Blood 2008; 111: 1387-1395.
67. Sabbah S, Jagne YJ, Zuo J, et al. T-cell immunity to Kaposi sarcoma-associated herpesvirus: Recognition of primary effusion lymphoma by LANA-specific CD4+ T cells. Blood 2012; 119: 2083-2092.
68. Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol 2010; 342: 341-357.
69. Laing KJ, Dong L, Sidney J, Sette A, Koelle DM. Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses. Clin Exp Immunol 2012; 167: 47-58.
70. Malavige GN, Jones L, Black AP, Ogg GS. Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol 2008; 152: 522-531.
71. Koelle DM, Liu Z, McClurkan CM, et al. Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. J Clin Invest 2002; 110: 537-548.
72. Jones L, Black AP, Malavige GN, Ogg GS. Phenotypic analysis of human CD4+ T cells specific for immediate-early 63 protein of varicella-zoster virus. Eur J Immunol 2007;37:3393-3403.
73. Derfuss T, Arbusow V, Strupp M, Brandt T, Theil D. The presence of lytic HSV-1 transcripts and clonally expanded T cells with a memory effector phenotype in human sensory ganglia. Ann N Y Acad Sci 2009; 1164: 300-304.
74. Verjans GM, Hintzen RQ, van Dun JM, et al. Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A 2007; 104: 3496-3501.
75. Hislop AD, Kuo M, Drake-Lee AB, et al. Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance. J Clin Invest 2005; 115: 2546-2555.
76. Knickelbein JE, Khanna KM, Yee MB, Baty CJ, Kinchington PR, Hendricks RL. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science 2008; 322: 268-271.
77. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357: 1903-1915.
78. Amanna IJ, Slifka MK. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010; 236: 125-138.
79. Aberle JH, Puchhammer-Stockl E. Age-dependent increase of memory B cell response to cytomegalovirus in healthy adults. Exp Gerontol 2012; 47: 654-657.
80. Potzsch S, Spindler N,Wiegers AK, et al. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog 2011; 7: e1002172.
81. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): Use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 1990; 64: 1079-1085.
82. UrbanM, Klein M, BrittWJ, Hassfurther E, Mach M. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 1996; 77 (Pt 7): 1537-1547.
83. Macagno A, Bernasconi NL, Vanzetta F, et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 2010; 84: 1005-1013.
84. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009; 360: 1191-1199.
85. Arora N, Novak Z, Fowler KB, Boppana SB, Ross SA. Cytomegalovirus viruria and DNAemia in healthy seropositive women. J Infect Dis 2010; 202: 1800-1803.
86. Manuel O, Asberg A, Pang X, et al. Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solidorgan transplant recipients with cytomegalovirus disease. Clin Infect Dis 2009; 49: 1160-1166.
87. Ross SA, Arora N, Novak Z, Fowler KB, Britt WJ, Boppana SB. Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 2010; 201: 386-389.
88. Sauerbrei A, Stefanski J, Gruhn B, Wutzler P. Immune response of varicella vaccinees to different varicella-zoster virus genotypes. Vaccine 2011; 29: 3873-3877.
89. Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al. Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 2007; 196: 1749-1753.
90. Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012; 366: 34-43.
91. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein- D-adjuvant vaccine to prevent genital herpes. N Engl JMed 2002; 347: 1652-1661.
92. Hsu DH, de Waal Malefyt R, Fiorentino DF, et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 1990; 250: 830-832.
93. Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci U S A 2000; 97: 1695-700.
94. Kuhn DE, Beall CJ, Kolattukudy PE. The cytomegalovirus US28 protein binds multiple CC chemokines with high affinity. Biochem Biophys Res Commun 1995; 211: 325-330.
95. Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 123-133.
96. Tomasec P, Braud VM, Rickards C, et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000; 287: 1031-1033.
97. Jones TR, Sun L. Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. J Virol 1997; 71: 2970-2979.
98. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 1996; 84: 769-779.
99. Ahn K, Gruhler A, Galocha B, et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 1997; 6: 613-621.
100. Jones TR, Wiertz EJ, Sun L, Fish KN, Nelson JA, Ploegh HL. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci U S A 1996; 93: 11327-1133.
101. Furman MH, Dey N, Tortorella D, Ploegh HL. The human cytomegalovirus US10 gene product delays trafficking of major histocompatibility complex class I molecules. J Virol 2002; 76: 11753-11756.
102. Kim S, Lee S, Shin J, et al. Human cytomegalovirus microRNA miR-US4-1 inhibits CD8(+) T cell responses by targeting the aminopeptidase ERAP1. Nat Immunol 2011;12:984-991.
103. Avdic S, Cao JZ, Cheung AK, Abendroth A, Slobedman B. Viral interleukin-10 expressed by human cytomegalovirus during the latent phase of infection modulates latently infected myeloid cell differentiation. J Virol 2011; 85: 7465-7471.
104. Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol 1997; 71: 4882-4891.
105. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257: 238-241.
106. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362: 1375-1377.
107. Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A 1999; 96: 10391-10396.
108. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virusspecific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
109. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-1555.
110. Crough T, Khanna R. Immunobiology of human cytomegalovirus: From bench to bedside. Clin Microbiol Rev 2009; 22: 76-98.
111. Harrop R, Ryan MG, Golding H, Redchenko I, Carroll MW. Monitoring of human immunological responses to vaccinia virus. Methods Mol Biol 2004; 269: 243-266.
112. Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002; 25: 97-138.
113. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
114. Crough T, Fazou C, Weiss J, et al. Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8(+) T-cell response. J Virol 2007;81:11538-11542.
115. Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9: 1214-1222.
116. Nebbia G, Mattes FM, Smith C, et al. Polyfunctional cytomegalovirus- specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation. Am J Transplant 2008; 8: 2590-2599.
117. Mattes FM, Vargas A, Kopycinski J, et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant 2008; 8: 990-999.
118. Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201): 1031-1036.
119. Sherritt MA, Bharadwaj M, Burrows JM, et al. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation 2003; 75: 1556-1560.
120. Pipeling MR, John ER, Orens JB, Lechtzin N, McDyer JF. Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients. J Infect Dis 2011; 204: 1663-1671.
121. La Rosa C, Krishnan A, Longmate J, et al. Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. J Infect Dis 2008; 197: 25-33.
122. Hertoghs KM,Moerland PD, van Stijn A, et al.Molecular profiling of cytomegalovirus-induced human CD8+ T cell differentiation. J Clin Invest 2010; 120: 4077-4090.
123. Walker S, Fazou C, Crough T, et al. Ex Vivo Monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERONR-CMV. Transplant Infect Dis 2007; 9: 165-170.
124. Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8(+) T-cell immunity. Am J Transplant 2008; 8: 1749-1758.
125. Adler SP, Nigro G. Findings and conclusions from CMV hyperimmune globulin treatment trials. J Clin Virol 2009; 46(Suppl 4): S54-S57.
126. Snydman DR. Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Rev Infect Dis 1990; 12(Suppl 7): S839-S848.
127. Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A. CMVhyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: A meta-analysis. Clin Transplant 2008; 22: 89-97.
128. Agah R, Charak BS, Chen V, Mazumder A. Adoptive transfer of anti-cytomegalovirus effect of interleukin-2-activated bone marrow: Potential application in transplantation. Blood 1991; 78: 720-727.
129. Hill GR, Tey SK, Beagley L, et al. Successful immunotherapy of HCMV disease using virus-specific T cells expanded from an allogeneic stem cell transplant recipient. Am J Transplant 2010; 10: 173-179.
130. Brestrich G, Zwinger S, Fischer A, et al. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant 2009; 9: 1679-1684.
131. Savoldo B, Rooney CM, Quiros-Tejeira RE, et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am JTransplant 2005; 5: 566-572.
132. Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 1999; 96: 10391-10396.
133. Smith C, Tsang J, Beagley L, et al. Effective treatment of metastatic forms of epstein-barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res 2012; 72: 1116-1125.
134. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202: 379-386.
135. Haque T,Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2multicenter clinical trial. Blood 2007; 110: 1123-1131.
136. Melenhorst JJ, Leen AM, Bollard CM, et al. Allogeneic virusspecific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 2010; 116: 4700-4702.
137. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23: 225-274.
138. van Stijn A, Rowshani AT, Yong SL, et al. Human cytomegalovirus infection induces a rapid and sustained change in the expression of NK cell receptors on CD8+ T cells. J Immunol 2008; 180: 4550-4560.
139. Grubor-Bauk B, Simmons A, Mayrhofer G, Speck PG. Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant V alpha 14-J alpha 281 TCR. J Immunol 2003; 170: 1430-1434.
140. Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4(+) T cells in immunity to viruses. Nat Rev Immunol 2012; 12: 136-148.
141. Crompton L, Khan N, Khanna R, Nayak L, Moss PA. CD4+ T cells specific for glycoprotein B from cytomegalovirus exhibit extreme conservation of T-cell receptor usage between different individuals. Blood 2008; 111: 2053-2061.
142. de Bree GJ, van Leeuwen EM, Out TA, Jansen HM, Jonkers RE, van Lier RA. Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung. J Exp Med 2005; 202: 1433-1442.
143. Gebhardt T, Whitney PG, Zaid A, et al. Different patterns of peripheral migration by memory CD4+ and CD8+ T cells. Nature 2011; 477: 216-219.
144. Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 2008; 20: 67-82.
145. Le VT, Trilling M, Wilborn M, Hengel H, Zimmermann A. Human cytomegalovirus interferes with signal transducer and activator of transcription (STAT) 2 protein stability and tyrosine phosphorylation. J Gen Virol 2008; 89(Pt 10): 2416-2426.
146. Margulies BJ, Browne H, Gibson W. Identification of the human cytomegalovirus G protein-coupled receptor homologue encoded by UL33 in infected cells and enveloped virus particles. Virology 1996; 225: 111-125.
147. Rezaee SA, Cunningham C, Davison AJ, Blackbourn DJ. Kaposi's sarcoma-associated herpesvirus immune modulation: An overview. J Gen Virol 2006; 87(Pt 7): 1781-1804.
148. Fruh K, Ahn K, Djaballah H, et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995;375:415-418.
149. Hislop AD, Ressing ME, van Leeuwen D, et al. A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 2007; 204: 1863-1873.
150. Eisfeld AJ, Yee MB, Erazo A, Abendroth A, Kinchington PR. Downregulation of class I major histocompatibility complex surface expression by varicella-zoster virus involves open reading frame 66 protein kinase-dependent and -independent mechanisms. J Virol 2007; 81: 9034-9049.
151. Rowe M, Glaunsinger B, van Leeuwen D, et al. Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci U S A 2007; 104: 3366-3371.
152. Zuo J, Currin A, Griffin BD, et al. The Epstein-Barr virus G-proteincoupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog. 2009; 5: e1000255.
153. Coscoy L, Sanchez DJ, Ganem D. A novel class of herpesvirusencoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition. J Cell Biol 2001; 155: 1265-1273.
154. Kwun HJ, da Silva SR, Shah IM, Blake N, Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mimics Epstein-Barr virus EBNA1 immune evasion through central repeat domain effects on protein processing. J Virol 2007; 81: 8225-8235.
155. Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375: 685-688.
156. Thomas M, Boname JM, Field S, et al. Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc Natl Acad Sci U S A 2008; 105: 1656-1661.
157. Chapman TL, Heikeman AP, Bjorkman PJ. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity 1999; 11: 603-613.
158. Khanna R, Burrows SR, Moss DJ, Silins SL. Peptide transporter (TAP- and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: Implications for cytotoxic T-lymphocyte control of EBV-associated malignancies. J Virol 1996; 70: 5357-5362.
159. Lautscham G, Haigh T, Mayrhofer S, et al. Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2. J Virol 2003; 77: 2757-2761.
160. English L, Chemali M, Duron J, et al. Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection. Nat Immunol 2009; 10: 480-487.
161. Bell MJ, Abbott RJ, Croft NP, Hislop AD, Burrows SR. An HLA-A2- restricted T-cell epitope mapped to the BNLF2a immune evasion protein of Epstein-Barr virus that inhibits TAP. J Virol 2009; 83: 2783-2788.
162. Saulquin X, Bodinier M, Peyrat MA, et al. Frequent recognition of BCRF1, a late lytic cycle protein of Epstein-Barr virus, in the HLAB&z.ast; 2705 context: Evidence for a TAP-independent processing. Eur J Immunol 2001; 31: 708-715.
163. Pietra G, Romagnani C, Mazzarino P, et al. HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proc Natl Acad Sci U S A 2003; 100: 10896-10901.